Iwan Bertholjotti1. Show Affiliations » 1. LCMC Lonza AG, Rottenstrasse 6, CH-3930 Visp. iwan.bertholjotti@lonza.com
Abstract
Entities: Disease
Mesh: See more » Ado-Trastuzumab EmtansineAntibodies, Monoclonal, Humanized/therapeutic useAntineoplastic Agents/therapeutic useBrentuximab VedotinClinical Trials as TopicHumansImmunoconjugates/therapeutic useMaytansine/analogs & derivativesMaytansine/therapeutic useNeoplasms/drug therapyNeoplasms/mortalityPrecision Medicine/methodsTrastuzumabTreatment Outcome
Substances: See more » Antibodies, Monoclonal, HumanizedAntineoplastic AgentsImmunoconjugatesMaytansineBrentuximab VedotinTrastuzumabAdo-Trastuzumab Emtansine
Year: 2011 PMID: 22026193 DOI: 10.2533/chimia.2011.746
Source DB: PubMed Journal: Chimia (Aarau) ISSN: 0009-4293 Impact factor: 1.509